Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2008 Aug 6;7(8):2272–2279. doi: 10.1158/1535-7163.MCT-08-0182

Figure 1.

Figure 1

Analysis of molecular targets of cediranib and vandetanib in T241 tumor cell lines. A) Analysis of exogenous VEGF-C gene expression and other endogenous gene expression in T241 transfectants. The amplified cDNA products generated by RT-PCR analysis of total RNA from T241-GFP cells, T241-VEGF-C-GFP cells and murine embryo cells (as positive control) by oligonucleotide primers that recognize the specific genes indicated. B) Immunostaining of VEGFR-2, VEGFR-3 and PDGFR-β in T241-VEGF-C-GFP ear tumor. While VEGFR-2, VEGFR-3 and PDGFR-β expression were not detected in tumor cells, VEGFR-2 expression was detected on most tumor blood vessels and VEGFR-3 and PDGFR-β on a fraction of tumor blood vessels.